Table 2. Multivariate analysis.
Variable | Non-PSM | PSM | |||||
---|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | ||
Age | 1.01 | 1.00–1.01 | <0.001 | 1.01 | 1.01–1.02 | <0.001 | |
Gender | |||||||
Male | REF | REF | REF | REF | REF | REF | |
Female | 0.99 | 0.93–1.05 | 0.73 | 0.94 | 0.84–1.04 | 0.22 | |
Charlson/Deyo | |||||||
0 | REF | REF | REF | REF | REF | REF | |
1 | 1.07 | 1.00–1.14 | 0.06 | 1.14 | 1.01–1.28 | 0.04 | |
2 | 1.11 | 0.97–1.25 | 0.12 | 1.35 | 1.03–1.77 | 0.03 | |
Path T-stage | |||||||
T0 | REF | REF | REF | REF | REF | REF | |
T1 | 0.49 | 0.20–1.20 | 0.12 | 0.46 | 0.15–1.45 | 0.19 | |
T2 | 0.47 | 0.19–1.13 | 0.09 | 0.4 | 0.13–1.27 | 0.12 | |
T3 | 0.52 | 0.22–1.25 | 0.15 | 0.48 | 0.15–1.50 | 0.21 | |
T4 | 0.71 | 0.28–1.76 | 0.45 | 0.55 | 0.16–1.85 | 0.33 | |
Path N-stage | |||||||
N0 | REF | REF | REF | REF | REF | REF | |
N1 | 1.59 | 1.50–1.69 | <0.001 | 1.48 | 1.31–1.68 | <0.001 | |
Grade | |||||||
Low | REF | REF | REF | REF | REF | REF | |
Intermediate | 1.22 | 1.09–1.37 | 0.001 | 1.25 | 1.03–1.51 | 0.02 | |
High | 1.58 | 1.41–1.77 | <0.001 | 1.76 | 1.44–2.13 | <0.001 | |
Tumor size | |||||||
≤2 cm | REF | REF | REF | REF | REF | REF | |
>2 cm | 1.35 | 1.22–1.49 | <0.001 | 1.45 | 1.28–1.64 | <0.001 | |
Surgical margins | |||||||
R0 | REF | REF | REF | REF | REF | REF | |
R1/R2 | 1.39 | 1.30–1.50 | <0.001 | 1.54 | 1.35–1.75 | <0.001 | |
Facility volume | |||||||
Low (<10/yr) | REF | REF | REF | REF | REF | REF | |
Med (11–19/yr) | 0.96 | 0.89–1.03 | 0.22 | 1.02 | 0.91–1.16 | 0.7 | |
High (>20/yr) | 0.92 | 0.85–0.99 | 0.03 | 0.91 | 0.79–1.06 | 0.22 | |
Treatment | |||||||
Def surgery, adjv | REF | REF | REF | REF | REF | REF | |
Neo chemo | 0.92 | 0.80–1.06 | 0.27 | 0.69 | 0.49–0.99 | 0.04 | |
Neo chemo/rad | 1.1 | 0.98–1.25 | 0.12 | 1.35 | 1.09–1.67 | 0.006 |